Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05096663
Title Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

lung non-small cell carcinoma

Therapies

Dexamethasone + Docetaxel + Gemcitabine + Pemetrexed Disodium + Ramucirumab

ALT-803 + Pembrolizumab

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.